Lobe Sciences Announces Update on Corporate Slide Deck Highlighting its Psilocin Compounds and Development Plans

Mydecine Innovations Group Announces Private Placement; Interim Changes to Management and Board of Directors

PharmaDrug Successfully Completes Key Milestone to Support cGMP Production of Clinical Lead Candidate PD-001, Its Patented, Orally Available Version of Cepharanthine for Oncology and Infectious Disease

Universal Ibogaine Provides Update on Kelburn Recovery Center

Algernon Pharmaceuticals Announces Private Placement

Wellbeing Corporate Update in a Letter from the CEO to its Shareholders

Small Pharma Announces TSXV Approval of Normal Course Issuer Bid

Awakn Life Sciences Signs Second Licensing Partnership Agreement and Expands Commercial Operations Into Canada

Psyched Wellness Announces Marketing Agreement with North Equities Corp. and Issuance of Restricted Share Units

HAVN Life Announces the close of the first tranche of its previously announced Financing Commitment by Alpha Blue Ocean and Warrant Amendments‎ and the Issuance of Shares for Debt

Core One Labs' Akome Achieves Significant Research Milestone with Positive Neurogenesis Stimulation Studies Results

Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial

Filament Health Announces Eighth Patent Issuance

PharmAla Biotech First Publicly Traded Company to Produce GMP MDMA

Core One Labs’ Vocan Successfully Converts Psilocin Precursor into Psilocybin

Delic Announces Two Key Executive Appointments